match-repair genes ( Fig. 2 and 3 ). The inactivation can be inherited, as in hereditary nonpolyposis colon cancer (HNPCC), also known as the Lynch syndrome, or acquired, as in tumors with methylation-associated silencing of a gene that encodes a DNA mismatch-repair protein.
In patients with HNPCC, germ-line defects in mismatch-repair genes (primarily MLH1 and MSH2) confer a lifetime risk of colorectal cancer of about 80%, with cancers evident by the age of 45 years, on average. [10] [11] [12] [13] 30, 31 The loss of mismatch-repair function in patients with HNPCC is due not only to the mutant germ-line mismatchrepair gene but also to somatic inactivation of the wild-type parental allele. 31 Genomic instability arising from mismatch-repair deficiency dramatically accelerates the development of cancer in patients with HNPCC -some cancers arise within 36 months after normal results on colonoscopy. 32 For this reason, yearly colonoscopy is recommended for carriers of an HNPCC mutation, 30, 32 and prophylactic colectomy should be considered for patients with high-grade lesions. Germ-line mutations of another mismatch-repair gene, MSH6, attenuates the predisposition to familial cancer. 9, 33, 34 Somatic inactivation of mismatch-repair genes occurs in approximately 15% of patients with nonfamilial colorectal cancer. In these patients, biallelic silencing of the promoter region of the MLH1 gene by promoter methylation inactivates mismatch repair [15] [16] [17] (Fig.  2 and 3) .
The loss of mismatch-repair function is easy to recognize by the associated epiphenomenon of microsatellite instability, in which the inability to repair strand slippage within repetitive DNA sequence elements changes the size of the mononucleotide or dinucleotide repeats (microsatellites) that are scattered throughout the genome. Mismatch-repair deficiency can also be detected by immunohistochemical analysis, which can identify the loss of one of the mismatchrepair proteins. 14, [35] [36] [37] Cancers characterized by mismatch-repair deficiency arise primarily in the proximal colon, and in sporadic cases, they are associated with older age and female sex. 30 In mismatch-repair deficiency, tumor-suppressor genes, such as those encoding transforming growth factor β (TGF-β) receptor type II (TGFBR2) and BCL2-associated X protein (BAX), which have functional regions that contain mononucleotide or dinucleotide repeat sequences, can be inactivated. 2, 27, 28 An alternative route to colorectal cancer involves germ-line inactivation of a base excision repair gene, mutY homologue (MUTYH, also called MYH). 25, 33 The MYH protein excises from DNA the 8-oxoguanine product of oxidative damage to guanine. 24, 25, 33 In persons who carry two inactive germ-line MYH alleles, a polyposis phenotype develops, with a risk of colorectal cancer of nearly 100% by the age of 60 years. 33 MYH-associated polyposis is increasingly recognized: one third of all persons in whom 15 or more colorectal adenomas develop have MYHassociated polyposis. 33 The diagnosis requires genetic testing, which is facilitated by two mutations, Y165C and G382D, that together account for 85% of cases. 33 Thus far, somatic inactivation of MYH has not been detected in colorectal cancer.
nism of gene inactivation in patients with colorectal cancer. 18,20 A methylated form of cytosine in which a methyl group is attached to carbon 5 (5-methylcytosine) defines a fifth DNA base, introduced by DNA methylases that modify cytosines within CpG dinucleotides. 18 In the normal genome, cytosine methylation occurs in areas of repetitive DNA sequences outside of exons; it is largely excluded from the CpG-rich "CpG islands" in the promoter regions of approximately half of all genes. 18 By comparison, in the colorectal-cancer genome, there is a modest global depletion of cytosine methylation but considerable acquisition of aberrant methylation within certain promoterassociated CpG islands. 18 This aberrant promoterassociated methylation can induce epigenetic silencing of gene expression. 18 In sporadic colorectal cancer with microsatellite instability, somatic epigenetic silencing blocks the expression of MLH1. 18 Among the loci that can undergo aberrant methylation in colorectal cancer, a subgroup seems to become aberrantly methylated as a group, a phenomenon called the CpG island methylator phenotype (CIMP, or CIMP-high) . 18, 19 The molecular mechanism for CIMP remains unknown, but the phenomenon is reproducibly observed in about 15% of colorectal cancers and is present in nearly all such tumors with aberrant methylation of MLH1 18, 19, 21, 38 ( Fig. 2 and 3) . The pathogenetic consequence of MLH1 silencing is well established, but the contribution of other epigenetic silencing events to colorectal carcinogenesis remains an area of ongoing study. An intermediate level of aberrant methylation in CIMP may define a subtype (i.e., CIMP2 and CIMP-low) that is thought to account for 30% of CIMP cases. 22,23 A third pattern of aberrant methylation is exemplified by exon 1 of the gene encoding vimentin. Although this locus is not expressed by normal colon mucosa or colorectal cancer, it is aberrantly methylated in 53 to 83% of patients with colorectal cancer in a pattern that is independent of CIMP. 39, 40 Mu tationa l Inac ti vation of T umor-Suppr essor Genes
APC
Colorectal cancers acquire many genetic changes, but certain signaling pathways are clearly singled 
TP53
The inactivation of the p53 pathway by mutation of TP53 is the second key genetic step in colorectal cancer. In most tumors, the two TP53 alleles are inactivated, usually by a combination of a missense mutation that inactivates the transcriptional activity of p53 and a 17p chromosomal deletion that eliminates the second TP53 allele. 2, 27, 28, 44, 45 Wild-type p53 mediates cell-cycle arrest and a cell-death checkpoint, which can be activated by multiple cellular stresses. 63 The inactivation of TP53 often coincides with the transition of large adenomas into invasive carcinomas. 64 In many colorectal cancers with mismatch-repair defects, TP53 remains wild-type, though in these cancers the activity of the p53 pathway is probably attenuated by mutations in the BAX inducer of apoptosis. 2,28
TGF-β Tumor-Suppressor Pathway
The mutational inactivation of TGF-β signaling is a third step in the progression to colorectal cancer. 50 In about one third of colorectal cancers, somatic mutations inactivate TGFBR2. 47, 49, 50, 65, 66 In tumors with mismatch-repair defects, TGFBR2 is inactivated by distinctive frameshift mutations in a polyadenine repeat within the TGFBR2 coding sequence. 47 In at least half of all colorectal cancers with wild-type mismatch repair, TGF-β signaling is abolished by inactivating missense mutations that affect the TGFBR2 kinase domain or, more commonly, mutations and deletions that inactivate the downstream TGF-β pathway component SMAD4 or its partner transcription factors, SMAD2 and SMAD3. 29, 47, [49] [50] [51] [65] [66] [67] [68] Mutations that inactivate the TGF-β pathway coincide with the transition from adenoma to high-grade dysplasia or carcinoma. 69
Ac ti vation of Oncogene Path wa ys
RAS and BRAF
Several oncogenes play key roles in promoting colorectal cancer ( Fig. 2 and Shown are the overlapping relationships that define the major pathways of genomic instability in colon cancers: chromosomal instability, microsatellite instability caused by defects in DNA mismatch-repair genes that are either inherited as germ-line defects (e.g., in hereditary nonpolyposis colon cancer) or somatically acquired (e.g., by aberrant methylation and epigenetic silencing of MLH1), and the CpG island methylator phenotype.
The members of the Reference Sequence (RefSeq) database of the National Center for Biotechnology Information. 65, 66 Cancer-associated somatic mutations were identified in 848 genes. Of these, 140 were identified as candidate cancer genes that probably contributed to the cancer phenotype because they were mutated in at least two colorectal cancers and when corrected for gene size showed more mutations than expected by chance. The average stage IV colorectal-cancer genome bears 15 mutated candidate cancer genes and 61 mutated passenger genes (very-low-frequency mutational events). The predominance of low-frequency mutations in candidate cancer genes implies enormous genetic heterogeneity among colorectal cancers, which mirrors the heterogeneity of the clinical behavior of colorectal cancers.
The high degree of genetic heterogeneity makes it difficult to determine the clinical effect of individual mutational events. Moreover, these initial results are probably conservative, because some mutations, which were initially labeled as rare "passengers" in colorectal cancer, have subsequently emerged as common and are probably pathogenetic in other cancer types (e.g., an IDH1 mutation noted initially in one colorectal cancer but subsequently in many gliomas). 65, 66, 74 High-throughput sequencing of the colorectalcancer genome has identified new common mutational targets. These include the ephrin receptors EPHA3 and EPHB6 (receptor tyrosine kinases), which together are mutated in 20% of colorectal cancers, and FBXW7, which functions in a protein degradation pathway that regulates levels of cy- clin E and is mutated in 14% of colorectal cancers. 65, 66, 75 An important challenge is to reduce the complexity of the 140 candidate cancer genes by identifying the biologic pathways and processes that are common downstream targets of multiple mutational events.
Genomic Ch a nges a nd T umor Progr ession
The sequence of transformation from adenoma to carcinoma, as initially formulated, 2,28,43 was a model of the development of colorectal cancer in which specific tumor-promoting mutations are progressively acquired. This model predicts the presence of mutations that dictate specific tumor characteristics, such as the presence of regional or distant metastases (Fig. 2) . Unexpectedly, the examination of results of full-genome sequencing from primary colorectal cancers and distant metastases in the same patient showed no new mutations in the metastases, 76 implying that new mutations are not required to enable a tumor cell to leave the primary tumor and seed a distant site. Because the ongoing generation of mutations serves as a molecular clock, the finding that all the mutations in a metastasis are also present in the primary tumor implies that metastatic seeding is rapid, requiring less than 24 months from the appearance of the final mutation in the primary tumor. 76 
Grow th Fac t or Path ways

Aberrant Regulation of Prostaglandin Signaling
The activation of growth factor pathways is common in colorectal cancer (Fig. 2 ). An early and critical step in the development of an adenoma is the activation of prostaglandin signaling. 77, 78 This abnormal response can be induced by inflammation or mitogen-associated up-regulation of COX-2, an inducible enzyme that mediates the synthesis of prostaglandin E 2 , an agent strongly associated with colorectal cancer. 78 Prostaglandin E 2 activity can also be increased by the loss of 15-prostaglandin dehydrogenase , the rate-limiting enzyme in catalyzing degradation of prostaglandin. [79] [80] [81] 95, 96 and the p110 subunit of PI3K 97 -do not respond to anti-EGFR therapy.
Vascular Endothelial Growth Factor
Vascular endothelial growth factor (VEGF) that is produced in states of injury or during the growth of normal tissue drives the production of new stromal blood vessels (angiogenesis). Clinical studies have suggested a role for angiogenic pathways in the growth and lethal potential of colorectal cancer. Treatment with the anti-VEGF antibody bevacizumab added an average of 4.7 months to the overall survival of patients with advanced colorectal cancer (15.6 months with standard therapy). 98 The identification of molecular distinctions between cancers that benefit from this treatment and those that do not remains a challenge.
S tem-Cell Path ways
Stem cells in colorectal cancers are believed to be uniquely endowed with the capacity to renew themselves. 
Pr edic ti v e a nd Prognos tic M a r k er s
One ongoing challenge is to translate the wealth of knowledge regarding colorectal-cancer genomics into clinically applicable predictive or prognostic tests (Table 3) . The relation between mutations in EGFR signaling components RAS and BRAF and anti-EGFR therapy is currently the only application of colorectal-cancer genomics to treatment. 
Nonin va si v e Molecul a r De tec tion
The development of molecular diagnostics for the early detection of colorectal cancer is an important translation of colon-cancer genetics into clinical practice. One example is the development of assays to detect mutations that are specific to colorectal cancer and cancer-associated aberrant DNA methylation in fecal DNA from patients with colorectal cancer or advanced adenomas. These assays have a sensitivity of 46 to 77% for detecting early-stage colorectal cancer, which is superior to the sensitivity of testing for fecal occult blood although their superiority in preventing death from cancer has not been shown. 39, [110] [111] [112] [113] Stool DNA testing for colorectal cancer has been added to the cancer-screening guidelines of the American Cancer Society 114 and appears to be equally sensitive for detecting advanced adenomas. 115 Although still in the developmental stage, assays for detecting plasma cell-free DNA may also be clinically useful, 115 and assays for tumor-specific plasma protein or RNA profiles also remain targets of research. Questions that remain to be resolved are Table 3 . Prognostic and Predictive DNA Markers in Colorectal Cancer.*
DNA Marker Comments
Prognostic APC A germ-line mutation defines the colorectal-cancer predisposition syndrome, familial adenomatous polyposis, with an 80 to 100% lifetime risk of colorectal cancer. Patients with germ-line APC mutations undergo prophylactic colectomy or proctocolectomy.
MLH1, MSH2, MSH6
A germ-line mutation in these and, less commonly, in other mismatch-repair genes defines hereditary nonpolyposis colon cancer, with a 40 to 80% lifetime risk of colorectal cancer, as well as an increased risk of endometrial cancer. Patients with germ-line mismatch-repair gene mutations undergo frequent colonoscopic surveillance and may be considered for prophylactic colectomy and hysterectomy.
MLH1 methylationassociated silencing
The somatic inactivation of MLH1 in primary colorectal cancers is evidenced by either detection of DNA microsatellite instability or loss of tumor MLH1 protein expression on immunohistochemical analysis, and is more frequent in early-stage colorectal cancers than in advanced disease. Such inactivation may be a marker of more indolent disease or a better prognosis in the absence of adjuvant chemotherapy.
103,104
18q Loss of heterozygosity The somatic loss of heterozygosity at chromosomal location 18q, a site containing genes associated with colorectal cancer (e.g., SMAD4 and SMAD2), is associated with a poorer outcome in patients with stage II or stage III colon cancer than that in patients with tumors retaining both parental alleles at 18q.
105
Predictive
KRAS
The somatic mutation produces unrestricted activity of signaling through the MAPK and PI3K cascades. Patients with stage IV colorectal cancer and activating mutations in KRAS do not have a response to EGFR-inhibitor therapy.
92-94
BRAF V600E
The somatic mutation activating this kinase causes unrestricted MAPK pathway signaling. Patients with stage IV colorectal cancer and the activating BRAF V600E mutation do not have a response to EGFR-inhibitor therapy.
95
MLH1 methylationassociated silencing
The loss of the mismatch-repair function contributes to the loss of other tumor suppressors (e.g., TGFBR2 and BAX). Patients with mismatch-repair-deficient tumors may not have a response to fluorouracil and may have an improved response to irinotecan-containing regimens.
106,107
* BAX denotes BCL2-associated X protein, EGFR epidermal growth factor receptor, MAPK mitogen-activated protein kinase, PI3K phosphatidylinositol 3-kinase, and TGFBR2 transforming growth factor receptor β type II. the optimal interval between serial tests and the performance and cost-effectiveness of stool DNA testing as compared with those of newer immunochemical fecal occult-blood tests. 116 Gene tic Influences in Popul ation Suscep tibilit y Genetic epidemiology and twin studies indicate that 35 to 100% of colorectal cancers and adenomas develop in persons with an inherited susceptibility to the disease. [117] [118] [119] In addition, an HNPCC-like syndrome occurs in some families without any evidence of defects in mismatch repair. 120 Several genomic loci that could harbor highly penetrant susceptibility genes have been identified with the use of linkage approaches, [121] [122] [123] but the underlying mutations are unknown. Genomewide association studies have also identified germ-line DNA variants that are strongly associated with susceptibility, but the clinical use of these results is probably limited, since the relative risk associated with these variants is low. [124] [125] [126] [127] [128] [129] Conclusions Studies that aid in the understanding of colorectal cancer on a molecular level have provided important tools for genetic testing for high-risk familial forms of the disease, predictive markers for selecting patients for certain classes of drug therapies, and molecular diagnostics for the noninvasive detection of early cancers. In addition, biologic pathways that could form the basis of new therapeutic agents have been identified. Although some high-frequency mutations are attractive targets for drug development, common signaling pathways downstream from these mutations may also be tractable as therapeutic targets. Recent progress in molecular assays for the early detection of colorectal cancer indicates that understanding the genes and pathways that control the earliest steps of the disease and individual susceptibility can contribute to clinical management in the near term.
An understanding of the signals that dictate the metastatic phenotype will provide the information necessary to develop drugs to control or prevent advanced disease. The considerable recent advances encourage us to believe that improvements in our knowledge of the molecular basis of colorectal cancer will continue to reduce the burden of this disease. 
108.
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